News >

FDA Grants Pembrolizumab Priority Review for Advanced SCLC

Gina Columbus @ginacolumbusonc
Published: Wednesday, Feb 20, 2019

Jonathan Cheng, MD

Jonathan Cheng, MD

The FDA has granted a priority review designation to a supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as a treatment for patients with advanced small cell lung cancer (SCLC) whose disease has progressed following ≥2 prior lines of therapy.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication